Tough guts of female mice point to colitis

MICHIGAN STATE (US) — Study shows female mice have a natural protection from certain digestive conditions, which may lead to new therapies for Crohn’s and other inflammatory bowel diseases.

While it’s tricky to draw conclusions for human health, the findings could eventually help scientists better understand and treat the 1.4 million Americans suffering from inflammatory bowel diseases, or IBD.

[sources]

Crohn’s disease and colitis, the two most common forms of IBD, involve abnormal functioning of the immune system that can damage the digestive tract, causing inflammation, diarrhea, constipation, abdominal pain, and other symptoms.

For the study, which appears in the journal Inflammatory Bowel Diseases, researchers induced colitis by giving mice with weakened immune systems a dose of bacteria that can cause digestive trouble. After six weeks, the males had significantly more severe symptoms than the females and had more of the bacteria left in their guts. The males also showed more deterioration of their bones, which studies have linked to gut inflammation.

“It seems females are protected from bad bacteria-induced bone loss, and it’s because they have reduced gut inflammation,” says co-author Laura McCabe, a professor in the Michigan State University’s Departments of Physiology and Radiology. “When we looked at markers of inflammation in the male mice, they were really high, whereas the females didn’t have that kind of bad response. They can somehow handle these nasty bacteria.”

McCabe says while the new study is a step toward better understanding of IBD, it’s not clear if women have the same kind of resistance to the condition as the female mice. Indeed, much is still unknown about IBD, including what causes it. The imbalance of good and bad gut bacteria that the experiment simulated is one possible cause.

“We want to know what it is about female mice allowing them to be protected,” she says. “If we can understand that, we might have a potential therapeutic target for people with IBD.”

The Crohn’s and Colitis Foundation of America funded the study.

Source: Michigan State University